istradefylline

Istradefylline (KW-6002)(Ki of 2.2 nM) is a selective adenosine A2A receptor (A2AR) antagonist, which is under development in Phase 3 trails. It has been used in trials studying the treatment and basic science of Drug Abuse, Sleep Disorder, Hepatic Impairment, Parkinson's Disease, and Restless Legs Syndrome, among others.

4-Desmethyl Istradefylline is a Istradefylline metabolite. Istradefylline is a very potent, selective, and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.

Istradefylline-13C,d3 is a carbon-13 and deuterium labeled form of istradefylline. Istradefylline acts as a potent and selective adenosine A2A receptor antagonist, which is orally bioavailable. It demonstrates efficacy in Parkinson's disease models, with a Ki value of 2.2 nM.

Istradefylline M1 Metabolite-[13C, D3] (Standard) is a reference standard of Istradefylline M1 Metabolite-[13C, D3] intended for quantitative analysis, quality control, and related biochemical research applications.

Istradefylline M8 Metabolite-[D4] (Standard) is a reference standard of Istradefylline M8 Metabolite-[D4] intended for quantitative analysis, quality control, and related biochemical research applications.